The resulting 124 I-evuzamitide (previously known as AT-01) has been shown to detect amyloidosis in organs like the heart, ...

About NEXICART-2 NEXICART-2 (NCT06097832) is an ongoing multi-site U.S. Phase 1/2 clinical trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory AL Amyloidosis, with a registrational ...

Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/ ...

A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a ...

A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a noninvasive assessment tool may help identify those at increased risk, ...

At age 76, I was diagnosed with sinus node dysfunction last year after several episodes of what I’d call being “spaced out” ...

INDICATION Attruby is a transthyretin stabilizer indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce ...

— G.W.T.Dear G.W.T.: The sinus of the heart has nothing to do with your nose as you might guess; it's a structure in the right atrium where blood flows into the heart from the venae cavae. It contains ...

Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced it will present new late-breaking data highlighting the clinical and economic ...

At age 76, I was diagnosed with sinus node dysfunction last year after several episodes of what I’d call being “spaced out” (for lack of a better term). I couldn’t explain these instances to myself, ...